Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × HDAC-42 × Clear all
NCT02569320 2021-06-15

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Plasma cell

Multiple Myeloma

NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Virginia Commonwealth University

Phase 1 Terminated
6 enrolled 12 charts
GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

NCT01798901 2018-03-14

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
13 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡